Refile: BUZZ-RedHill up as oral drug shows promise against radiation injury in study
17/11/2022 15:18
(Adds dropped word 'drug' in headline)
** U.S-listed shares of RedHill Biopharma RDHL.O up 7.2%
at 52 cents in early morning trading
** Co says data from pre-clinical study shows that its drug
opaganib can have protective impact on kidney function after
radiation exposure
** Adds that the drug works by creating conditions that
allow increased antitumor effects from radiation while
simultaneously suppressing inflammatory damage to healthy tissue
** Co says lab findings consistent with recently announced
efficacy data which shows opaganib's potential as a nuclear
radiation injury therapeutic
** RDHL has begun discussions for further support and
pathway to potential approval for the drug in this indication
with U.S., other governments
** RDHL is also testing its drug opaganib as a potential
treatment in conditions ranging from tumors to COVID-19
** Including session's gains, stock down 79.8% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))